سعر سبريسيل 50 مجم 60 قرص 2026

Sprycel (dasatinib) 50 mg film-coated tablets, pack of 60, Bristol-Myers Squibb; kinase inhibitor for Philadelphia chromosome-positive CML and ALL.

• Philadelphia chromosome-positive chronic myeloid leukaemia (newly diagnosed chronic phase, or resistant/intolerant any phase)Population: Adults; children 1 year and older (chronic phase)DailyMed (U.S. National Library of Medicine)
• Philadelphia chromosome-positive acute lymphoblastic leukaemia (resistant/intolerant in adults; newly diagnosed with chemotherapy in children)Population: Adults; children 1 year and olderDailyMed (U.S. National Library of Medicine)

• Most common (>=15%) with single-agent use: myelosuppression, fluid retention, diarrhoea, headache, skin rash, haemorrhage, dyspnoea, fatigue, nausea and musculoskeletal pain.International label, same product · DailyMed (U.S. National Library of Medicine)

• None stated in the US label.International label, same product · DailyMed (U.S. National Library of Medicine)

• Myelosuppression (severe thrombocytopenia, neutropenia, anaemia) and bleeding events (caution with antiplatelets/anticoagulants); fluid retention including pleural effusion; cardiovascular toxicity; pulmonary arterial hypertension (stop if confirmed); QT prolongation; severe dermatologic reactions; tumour lysis syndrome; embryo-fetal toxicity; effects on growth and bone development in children; hepatotoxicity.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole) and grapefruit juiceIncrease dasatinib exposure (ketoconazole: AUC about 5-fold); avoid; if unavoidable reduce dose (140 mg to 40 mg; 100 or 70 mg to 20 mg daily).DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (e.g. rifampin) and St John's wortDecrease dasatinib exposure (rifampin: AUC -82%); avoid or consider a dose increase with careful monitoring.DailyMed (U.S. National Library of Medicine)
• H2 antagonists and proton pump inhibitorsReduce dasatinib concentrations; do not coadminister.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: hydrops fetalis, fetal leukopenia and thrombocytopenia reported; transplacental transfer documented. Females of reproductive potential and males with such partners should use effective contraception during treatment and for 30 days after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• No human data; present in rat milk. Breastfeeding not recommended during treatment and for 2 weeks after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)

English text not available for this section.